Form 4 for CHRS Coherus Oncology, Inc.
Accepted 2023-01-06 00:00:00 ET · period of report 2023-01-04 · accession 0001567619-23-000698 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-06 | 2023-01-04 | CHRS | Lanfear Dennis M | Pres, CEO, Dir | F - Tax | $9.87 | -10.9K | 568.6K | -2% | -$107.6K |
| D | 2023-01-06 | 2023-01-05 | CHRS | Lanfear Dennis M | Pres, CEO, Dir | A - Grant | $0.00 | +402.5K | 402.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-04 | F | D | 10,905 | $9.87 | 568,603 | D | — | — | (F1) Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-01-05 | A | A | 402,500 | $0.00 | 402,500 | D | $10.37 · — to 2033-01-05 | 402,500 Common Stock | (F4) The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 5, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |